返回 
加入收藏
利奈唑胺联合常规抗结核药物治疗结核性脑膜炎有效性与安全性的Meta分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 利奈唑胺联合常规抗结核药物治疗结核性脑膜炎有效性与安全性的Meta分析 |
| TITLE： | Efficacy and Safety of Linezolid Combined with Routine Anti-tuberculosis Drugs for Tuberculous Meningitis ： A Meta-analysis |
| 摘要： | 目的：系统评价利奈唑胺（LZD）联合常规抗结核药治疗结核性脑膜炎（TBM）的疗效和安全性，为临床用药提供循证参考。方法：计算机检索PubMed、Cochrane图书馆、Embase、中国知网、万方数据等，收集LZD联合常规抗结核药物（试验组）对比常规抗结核药物（对照组）的随机对照试验（RCT），检索时限均为建库起至2020年1月。筛选文献、提取资料后，采用Cochrane系统评价员手册5.2推荐的偏倚风险评估工具对纳入文献质量进行评价，采用RevMan5.3软件进行Meta分析，并对结果进行敏感性分析和发表偏倚分析。结果：共纳入9项RCT，共计602例患者。Meta分析结果显示，试验组患者总有效率[OR＝4.05，95％CI（2.26，7.26），P＜0.00001]、脑脊液蛋白含量变化幅度[MD＝0.48，95％CI（0.20，0.77），P＝0.0008]、脑脊液白细胞计数变化幅度[MD＝44.43，95％CI（20.06，68.81），P＝0.0004]、脑脊液糖/同步血糖变化幅度[MD＝0.09，95％CI（0.05，0.14），P＜0.0001]均显著高于对照组，两组患者脑脊液氯化物含量变化幅度[MD＝8.08，95％CI（－0.64，16.80），P＝0.07]和不良反应发生率[OR＝1.34，95％CI（0.57，3.11），P＝0.50]比较，差异均无统计学意义。以脑积液蛋白含量变化幅度、脑脊液糖/同步血糖变化幅度为指标的敏感性分析结果显示，与剔除前比较有显著性差异；以脑脊液白细胞计数变化幅度、脑脊液氯化物含量变化幅度为指标的敏感性分析结果显示，与剔除前比较无显著性差异。发表偏倚分析结果显示，本研究存在一定的发表偏倚。结论：LZD联合常规抗结核药治疗TBM的疗效和安全性均较好。由于敏感性分析结果不一致，且存在发表偏倚，故所得结论尚需更多大样本、多中心研究进一步证实。 |
| ABSTRACT： | OBJECTIVE：To systematically evaluate the efficacy and safety of linezolid （LZD）combined with routine anti- tuberculosis drugs in the treatment of tuberculous meningitis （TBM），so as to provide evidence-based reference for clinical medi- cation. METHODS ：Retireved from PubMed ，Cochrane Library ，Embase，CNKI and Wanfang database ，randomized controlled trials（RCT）of LZD combined with routine anti-tuberculosis drugs （trial group ）versus routine anti-tuberculosis drugs （control group）were collected from the inception to Jan. 2020. After literature screening and data extraction ， the quality of the included literature were evaluated with bias risk assessment tool recommended by Cochrane system evaluator handbook 5.2. Meta-analysis was conducted by using Rev Man 5.3 software，and sensitivity analysis and publication bias analysis were performed. RESULTS ： Totally 9 RCTs involving 602 patients were included. Meta-analysis showed that total response rate [OR ＝4.05，95％CI（2.26，7.26）， P＜0.000 01]， changes of protein content of cerebrospinal fluid [MD ＝0.48，95％CI（0.20，0.77），P＝0.000 8]，changes of white blood cells count of cerebrospinal fluid [MD ＝44.43，95％CI（20.06，68.81），P＝0.000 4]，changes of cerebrospinal fluid glucose/ synchronous blood glucose [MD ＝0.09，95％CI（0.05，0.14），P＜0.000 1] of trial group were significantly higher than those of control group. There was no statistical significance in the changes of chloride content of cerebrospinal fluid [MD ＝8.08，95％CI（－0.64， 16.80），P＝0.07] and the incidence of ADR [OR ＝1.34，95％CI（0.57，3.11），P＝0.50] between 2 groups. The results of sensitivity analysis showed that there were significant differences comparison with before exclusion when the change of protein content in cerebrospinal fluid and the change of glucose/synchronous blood glucose in cerebrospinal fluid were taken as indexes ，and there was no significant difference comparison with before exclusion when the changes of white blood cell count and chloride content in cerebrospinal fluid were taken as indexes. The results of publication bias analysis showed that there was a certain publication bias in this study. CONCLUSIONS ：LZD combined with conventional anti-tuber culosis drugs is effective and safe for TBM. Because the inconsistent results of sensitivity analysis and publication bias exists in publication bias analysis ，the conclusions need to be further confirmed by more large sample and multi-center studies. |
| 期刊： | 2020年第31卷第22期 |
| 作者： | 文朋，程登贵，蒋其俊，罗雪，陈欢 |
| AUTHORS： | WEN Peng，CHENG Denggui ，JIANG Qijun，LUO Xue，CHEN Huan |
| 关键字： | 利奈唑胺；抗结核药物；结核性脑膜炎；Meta分析；疗效；安全性 |
| KEYWORDS： | Linezolid； Anti-tuberculosis drugs ； Tuber- |
| 阅读数： | 439 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
